Literature DB >> 15090810

Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre- and post-HAART eras.

Françoise Dromer, Simone Mathoulin-Pélissier, Arnaud Fontanet, Olivier Ronin, Bertrand Dupont, Olivier Lortholary.   

Abstract

OBJECTIVE: To analyse the epidemiological evolution of cryptococcosis in France after the introduction of highly active antiretroviral therapy (HAART).
DESIGN: Retrospective study of cryptococcosis cases recorded at the National Reference Center for Mycoses in France since 1985.
METHODS: Using the national surveillance data, we reviewed 1644 cases of HIV-associated cryptococcosis diagnosed in France (population, 59 million) between 1985 and 2001 and compared them to 335 cases recorded in HIV-negative patients.
RESULTS: The total number of cryptococcosis cases evolved in parallel to that recorded for HIV-infected patients. Changes occurring after HAART introduction were analysed. A negative binomial regression model established a 46% decrease of the incidence of cryptococcosis during the post-HAART era (1997-2001, n = 292) compared to the pre-HAART era (1985-1996, n = 1352). According to multivariate analysis, African origin, older age, heterosexual HIV contamination, no previous AIDS-defining illness, and no previous HIV infection diagnosis were variables independently associated with an increased risk of cryptococcosis during the post-HAART era. During the same period, the characteristics of the HIV-negative population did not change.
CONCLUSIONS: Our analysis of the national surveillance identified demographic factors associated with an increased risk of cryptococcosis in the post-HAART era suggesting that failure to consult and considering oneself not at risk were determinant in the current epidemiology of HIV-related cryptococcosis in France.

Entities:  

Mesh:

Year:  2004        PMID: 15090810     DOI: 10.1097/00002030-200402200-00024

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  52 in total

1.  Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.

Authors:  Patrick Schwarz; Françoise Dromer; Olivier Lortholary; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

2.  Evaluation of change in CD4+ cell counts in AIDS clinical trials.

Authors:  H Liang
Journal:  Stat Methods Med Res       Date:  2007-08-14       Impact factor: 3.021

Review 3.  Biosynthesis and immunogenicity of glucosylceramide in Cryptococcus neoformans and other human pathogens.

Authors:  Ryan Rhome; Travis McQuiston; Talar Kechichian; Alicja Bielawska; Mirko Hennig; Monica Drago; Giulia Morace; Chiara Luberto; Maurizio Del Poeta
Journal:  Eukaryot Cell       Date:  2007-08-10

4.  Identification and characterization of Cryptococcus neoformans protein fractions that induce protective immune responses.

Authors:  Ashok K Chaturvedi; Susan T Weintraub; Jose L Lopez-Ribot; Floyd L Wormley
Journal:  Proteomics       Date:  2013-12       Impact factor: 3.984

5.  Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis.

Authors:  E Dannaoui; M Abdul; M Arpin; A Michel-Nguyen; M A Piens; A Favel; O Lortholary; F Dromer
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

6.  Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial.

Authors:  Rosalind Parkes-Ratanshi; Katie Wakeham; Jonathan Levin; Deodata Namusoke; James Whitworth; Alex Coutinho; Nathan Kenya Mugisha; Heiner Grosskurth; Anatoli Kamali; David G Lalloo
Journal:  Lancet Infect Dis       Date:  2011-10-06       Impact factor: 25.071

7.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

8.  Use of a suspension array for rapid identification of the varieties and genotypes of the Cryptococcus neoformans species complex.

Authors:  Mara R Diaz; Jack W Fell
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

Review 9.  Bloodstream infections in HIV-infected patients.

Authors:  Lucia Taramasso; Paola Tatarelli; Antonio Di Biagio
Journal:  Virulence       Date:  2016-04-02       Impact factor: 5.882

10.  Environmental distribution of Cryptococcus neoformans and C. gattii around the Mediterranean basin.

Authors:  Massimo Cogliati; Roberta D'Amicis; Alberto Zani; Maria Teresa Montagna; Giuseppina Caggiano; Osvalda De Giglio; Stella Balbino; Antonella De Donno; Francesca Serio; Serdar Susever; Cagri Ergin; Aristea Velegraki; Mohamed S Ellabib; Simona Nardoni; Cristina Macci; Salvatore Oliveri; Laura Trovato; Ludovico Dipineto; Volker Rickerts; Ilka McCormick-Smith; Sevim Akcaglar; Okan Tore; Emilija Mlinaric-Missoni; Sebastien Bertout; Michele Mallié; Maria da Luz Martins; Ana C F Vencà; Maria L Vieira; Ana C Sampaio; Cheila Pereira; Giuseppe Criseo; Orazio Romeo; Stéphane Ranque; Mohammed H Y Al-Yasiri; Meltem Kaya; Nilgun Cerikcioglu; Anna Marchese; Luigi Vezzulli; Macit Ilkit; Marie Desnos-Ollivier; Vincenzo Pasquale; Maya Korem; Itzhack Polacheck; Antonio Scopa; Wieland Meyer; Kennio Ferreira-Paim; Ferry Hagen; Bart Theelen; Teun Boekhout; Shawn R Lockhart; Kathrin Tintelnot; Anna Maria Tortorano; Françoise Dromer; Ashok Varma; Kyung J Kwon-Chung; Joäo Inácio; Beatriz Alonso; Maria F Colom
Journal:  FEMS Yeast Res       Date:  2016-05-05       Impact factor: 2.796

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.